KR20250012078A - 상피 성장 인자 수용체 억제제의 염 및 결정 형태 - Google Patents

상피 성장 인자 수용체 억제제의 염 및 결정 형태 Download PDF

Info

Publication number
KR20250012078A
KR20250012078A KR1020247040290A KR20247040290A KR20250012078A KR 20250012078 A KR20250012078 A KR 20250012078A KR 1020247040290 A KR1020247040290 A KR 1020247040290A KR 20247040290 A KR20247040290 A KR 20247040290A KR 20250012078 A KR20250012078 A KR 20250012078A
Authority
KR
South Korea
Prior art keywords
egfr
mesylate salt
ray powder
powder diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247040290A
Other languages
English (en)
Korean (ko)
Inventor
에릭 그러프
샨밍 광
안잘리 판데이
하쉬 샤
티안 시에
Original Assignee
블루프린트 메디신즈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블루프린트 메디신즈 코포레이션 filed Critical 블루프린트 메디신즈 코포레이션
Publication of KR20250012078A publication Critical patent/KR20250012078A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247040290A 2022-05-04 2023-05-04 상피 성장 인자 수용체 억제제의 염 및 결정 형태 Pending KR20250012078A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04
US63/338,371 2022-05-04
PCT/US2023/020925 WO2023215431A1 (en) 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
KR20250012078A true KR20250012078A (ko) 2025-01-23

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040290A Pending KR20250012078A (ko) 2022-05-04 2023-05-04 상피 성장 인자 수용체 억제제의 염 및 결정 형태

Country Status (12)

Country Link
US (1) US20250282761A1 (enExample)
EP (1) EP4519254A1 (enExample)
JP (1) JP2025517634A (enExample)
KR (1) KR20250012078A (enExample)
CN (1) CN119923392A (enExample)
AU (1) AU2023265064A1 (enExample)
CA (1) CA3251624A1 (enExample)
IL (1) IL316663A (enExample)
MX (1) MX2024013485A (enExample)
TW (1) TW202409016A (enExample)
UY (1) UY40256A (enExample)
WO (1) WO2023215431A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097270A1 (en) * 2022-11-01 2024-05-10 Blueprint Medicines Corporation Egfr inhibitors for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
IL302457A (en) * 2020-10-30 2023-06-01 Blueprint Medicines Corp Pyrimidine compounds, preparations and their medical applications
CA3196857A1 (en) * 2020-10-30 2022-05-05 Gurulingappa Hallur Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
TW202409016A (zh) 2024-03-01
AU2023265064A1 (en) 2024-11-14
US20250282761A1 (en) 2025-09-11
MX2024013485A (es) 2024-12-06
IL316663A (en) 2024-12-01
WO2023215431A1 (en) 2023-11-09
EP4519254A1 (en) 2025-03-12
JP2025517634A (ja) 2025-06-10
CN119923392A (zh) 2025-05-02
CA3251624A1 (en) 2023-11-09
UY40256A (es) 2023-11-15

Similar Documents

Publication Publication Date Title
WO2021190467A1 (zh) 含螺环的喹唑啉化合物
TW202313034A (zh) Egfr抑制劑的鹽、晶型及其組合物和應用
US9630952B2 (en) Crystalline forms of afatinib di-maleate
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
JP2018511634A (ja) Ｂ−ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
WO2021213317A1 (zh) Hpk1抑制剂及其制备方法和用途
US20230331703A1 (en) Egfr inhibitors
EP4359400B1 (en) Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer
CN111763215A (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
JP2025538371A (ja) 含窒素複素環系化合物の薬用可能な塩、結晶型及び調製方法
KR20200032152A (ko) N-페닐-2-아미노피리미딘 화합물의 결정형과 염형, 및 이의 제조 방법
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
US20250282761A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
CN109593102A (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
EP4512808A1 (en) Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
EP4438600A1 (en) Compound used as kinase inhibitor and use thereof
TWI914461B (zh) 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
KR20250038235A (ko) 고체 형태의 jak 억제제 및 이의 제조 공정
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
TW201125861A (en) CDC7 inhibitor salts
TW202547497A (zh) 化合物的晶型、鹽型、溶劑合物、水合物及其用途
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
WO2025231053A1 (en) Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
JP2026502614A (ja) Ｃｄｋ阻害剤およびその薬学的に許容される塩の結晶形ならびにそれらの使用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000